Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions

1 references·16 citing·45 second hop

FromToDepth

this work references cited by second hop

References

2004Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis710 cited

Cited by

2017Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries306 cited
2010Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers255 cited
2015Attributes and weights in health care priority setting: A systematic review of what counts and to what extent179 cited
2012Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group161 cited
2010Population based screening for chronic kidney disease: cost effectiveness study160 cited
2017Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review121 cited
2015Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness116 cited
2010Facts, Fallacies, and Politics of Comparative Effectiveness Research: Part I. Basic Considerations110 cited
2016The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness105 cited
2016Health Economics at the Crossroads of Centuries – From the Past to the Future103 cited
2011The social value of a QALY: raising the bar or barring the raise?

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

98 cited

2012Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisions93 cited

2011Sensitivity Analysis in Cost-Effectiveness Studies92 cited

2012International Variability in the Reimbursement of Cancer Drugs by Publically Funded Drug Programs89 cited

2016Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries82 cited

2016Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland79 cited